# Lakewood-Amedex Biotherapeutics Inc. (LABT)

Source: https://www.quantisnow.com/company/LABT
Generated: 2026-11-07T05:48:33.653Z

- Ticker: LABT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0002079272

## Latest LABT news and filings

- 2026-11-05 13:02 UTC [Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-completion-of-series-c-convertible-preferred-stock-6774895)
- 2026-10-28 10:27 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Lakewood-Amedex Biotherapeutics with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-lakewood-amedex-biotherapeutics-with-a-new-6760304)
- 2026-10-21 12:02 UTC [Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-presents-data-highlighting-nu-3s-broad-spectrum-antimicrobial-activity-and-6753009)
- 2026-10-07 12:02 UTC [Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-positive-preclinical-data-in-urinary-tract-and-6739777)
- 2026-10-01 12:02 UTC [Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-participation-in-october-conferences-6731520)
- 2026-09-28 21:49 UTC [SEC Form 8-K] [Lakewood-Amedex Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-inc-filed-sec-form-8-k-submission-of-matters-6728209)
- 2026-09-28 12:02 UTC [Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-positive-data-against-recent-clinical-isolates-from-6727187)
- 2026-09-25 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lakewood-amedex-biotherapeutics-inc-6725937)
- 2026-09-24 12:02 UTC [Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-first-patient-dosed-in-phase-2a-clinical-6724880)
- 2026-09-21 12:02 UTC [Dividends] [Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-ceo-issues-letter-to-shareholders-highlighting-transformational-progress-6721269)
- 2026-09-18 21:30 UTC [SEC Form S-1] [SEC Form S-1 filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-lakewood-amedex-biotherapeutics-inc-6720873)
- 2026-09-18 12:13 UTC [Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-irb-approval-and-clinical-site-readiness-to-6720070)
- 2026-09-08 12:02 UTC [Conference Announcement] [Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-to-present-at-hc-wainwright-28th-annual-global-6707601)
- 2026-08-17 20:44 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-lakewood-amedex-biotherapeutics-inc-6685237)
- 2026-08-14 01:36 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lakewood-amedex-biotherapeutics-inc-6681647)
- 2026-08-10 21:14 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-lakewood-amedex-biotherapeutics-inc-6674301)
- 2026-08-10 21:13 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-lakewood-amedex-biotherapeutics-inc-6674296)
- 2026-07-30 20:31 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-lakewood-amedex-biotherapeutics-inc-6656422)
- 2026-07-22 12:02 UTC [Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-highlights-nu-3-resistance-data-in-response-to-national-6644709)
- 2026-07-15 20:15 UTC [SEC Form 8-K] [Lakewood-Amedex Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6638360)
- 2026-07-15 12:02 UTC [Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-preclinical-safety-data-supporting-clinical-dose-selection-6637647)
- 2026-07-07 12:02 UTC [Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-supports-reintroduction-of-the-pasteur-act-and-focus-6629503)
- 2026-06-26 12:35 UTC [Conference Announcement] [Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing](https://www.quantisnow.com/insight/life-sciences-virtual-investor-forum-presentations-now-available-for-on-demand-6616806)
- 2026-06-25 12:02 UTC [Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-world-renowned-expert-david-g-armstrong-md-phd-6615184)
- 2026-06-23 12:35 UTC [Conference Announcement] [Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th](https://www.quantisnow.com/insight/life-sciences-virtual-investor-forum-agenda-announced-for-june-24th-6612016)
- 2026-06-22 20:11 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-lakewood-amedex-biotherapeutics-inc-6610733)
- 2026-06-22 20:10 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-lakewood-amedex-biotherapeutics-inc-6610723)
- 2026-06-22 12:02 UTC [Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-secures-composition-of-matter-patent-protecting-new-bisphosphocin-6610094)
- 2026-06-17 15:40 UTC [SEC Form 8-K] [Lakewood-Amedex Biotherapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-inc-filed-sec-form-8-k-material-modification-to-6606245)
- 2026-06-16 12:02 UTC [Conference Announcement] [Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-to-present-at-life-sciences-virtual-investor-forum-6603955)
- 2026-05-27 12:02 UTC [Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers](https://www.quantisnow.com/insight/lakewood-amedex-expands-global-ip-portfolio-for-lead-candidate-nu-3-targeting-6573923)
- 2026-05-26 20:06 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-lakewood-amedex-biotherapeutics-inc-6572143)
- 2026-05-26 20:06 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-lakewood-amedex-biotherapeutics-inc-6572129)
- 2026-05-22 20:55 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lakewood-amedex-biotherapeutics-inc-6570354)
- 2026-05-18 12:02 UTC [Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-positive-data-for-the-advancement-of-lead-6559219)
- 2026-05-14 20:18 UTC [SEC Form 424B4 filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b4-filed-by-lakewood-amedex-biotherapeutics-inc-6554184)
- 2026-05-14 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Lakewood-Amedex Biotherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lakewood-amedex-biotherapeutics-inc-6552107)
- 2026-05-12 12:02 UTC [Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3](https://www.quantisnow.com/insight/lakewood-amedex-biotherapeutics-announces-agreement-with-peri-to-serve-as-cro-6546790)
- 2026-05-06 22:20 UTC [SEC Form 4] [SEC Form 4 filed by Director Tucker Joseph Edward](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-tucker-joseph-edward-6536711)
- 2026-05-06 22:19 UTC [SEC Form 3] [New insider Tucker Joseph Edward claimed no ownership of stock in the company (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-tucker-joseph-edward-claimed-no-ownership-of-stock-6536710)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LABT
- Earnings history: https://www.quantisnow.com/earnings/LABT
- Dividend history: https://www.quantisnow.com/dividends/LABT
- Insider transactions: https://www.quantisnow.com/insiders/LABT
- Options chain: https://www.quantisnow.com/options/LABT
- SEC 8-K filings only: https://www.quantisnow.com/company/LABT/8-k
- RSS and alerts for LABT: https://www.quantisnow.com/docs/rss-feeds.md